Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Qureight logo — Enterprise-grade imaging and precision endpoints for clinica...

Qureight

Enterprise-grade imaging and precision endpoints for clinical trials

Founded 2018 United Kingdom Cambridge, United Kingdom 58 employees Series B Total: $30.50M

General Information

Company Name Qureight
Founded Year 2018
Location United Kingdom Cambridge, United Kingdom +2
Employees 58
Funding Stage Series B
Social

Get notified when Qureight moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Qureight

Qureight is an innovative end-to-end imaging CRO that aims to transform the clinical trials landscape by accelerating processes for the biopharmaceutical industry. Their cutting-edge AI-powered platform specializes in the analysis and curation of clinical imaging and healthcare data specifically for patients suffering from lung and heart diseases. By offering enterprise-grade imaging and precision endpoints, Qureight enables faster market readiness for treatments.

Founded in 2018, Qureight operates out of Cambridge and London, UK, and focuses on therapeutic areas like Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension. The startup recently secured an $8.50M Series A investment, supported by a diverse group of investors including Playfair Capital, Cambridge Angels, and XTX Ventures. This investment underscores the confidence and potential seen in Qureight's mission to streamline clinical trial processes through advanced technology.

Taxonomy: Imaging CRO, Clinical Trials Acceleration, Enterprise-grade Imaging, Precision Endpoints, AI-powered Data Platform, Healthcare Data Analysis, Lung Disease Imaging, Heart Disease Imaging, Automated Image Management, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Bronchiectasis, Pulmonary Hypertension, Analytics Platform Development, Respiratory Disease Insights

Services & Products

Global imaging CRO services
AI-powered endpoints and analytics
Data science products
Automated image management
AI image analysis

Target Customers

Biopharmaceutical companies Clinical researchers Medical professionals Developers of lung and heart disease therapies

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor
•••• •••• 		29 Jul 2026
Series A •••••• 7
Investor Investor Investor Investor
•••• •••• 		01 Apr 2024
Seed •••••• 4
Investor Investor
•••• •••• 		01 Feb 2022
Seed •••••• 1
Investor
01 Sep 2021

Latest News

View All
Qureight raises $8.5M for clinical trial imaging to accelerate drug development — Tech
Qureight raises $8.5M for clinical trial imaging to accelerate drug development
Tech Apr 16, 2024
Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart... — Eu-startups
Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart disease
Eu-startups Apr 16, 2024
Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials — Tech
Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials
Tech Jul 29, 2026
This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials — Thenextweb
This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials
Thenextweb Jul 29, 2026

Qureight Alternatives & Competitors

View All Alternatives
Qureight vs
넥스트젠바이오사이언스
넥스트젠바이오사이언스

Pioneering breakthroughs in fibrosis treatment with innovative drugs tailored for various unmet medi...

4 employees
Biopharma, Health Care
Qureight vs
Alveolus Bio
Alveolus Bio United States

Harnessing the power of the live biotherapeutics and small molecules for the prevention and treatmen...

Grant
9 employees
Biotechnology
Compare Qureight vs Alveolus Bio
Qureight vs
Lung Therapeutics
Lung Therapeutics

Pioneering safer pathways in lung disease treatment with pharmaceutical solutions.

Series C
11-50 employees
Biotechnology, Health Care
Compare Qureight vs Lung Therapeutics
Also compare with: Qureight vs Melius Pharma Melius Pharma View all alternatives

FAQ About Qureight

Enterprise-grade imaging and precision endpoints for clinical trials
Qureight was founded in 2018.
Qureight is headquartered in Cambridge, United Kingdom.
Qureight has approximately 58 employees.
Qureight has completed 4 funding rounds, raising a total of $30.50M. The latest funding stage is Series B.
Qureight offers: Global imaging CRO services, AI-powered endpoints and analytics, Data science products, Automated image management, AI image analysis.
Top alternatives and competitors to Qureight include 넥스트젠바이오사이언스, Alveolus Bio, Lung Therapeutics, Melius Pharma, AnnJi Pharmaceutical Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Qureight and 넥스트젠바이오사이언스 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Qureight and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy